Today in Moscow, CEO of the Rostec State Corporation Sergey Chemezov and President of Marathon Group Alexander Vinokurov have signed the Shareholder Agreement on the National Immunobiological Company (Nacimbio) joint stock company. Earlier, on December 19, 2017, the deal was approved by the Supervisory Board of the Rostec State Corporation.
In accordance with the signed Shareholder Agreement, the corporate structure of Nacimbio is formed as follows: 75% minus one share of the authorized capital belong to Rostec, 25% plus one share belong to Marathon Group. Rostec represented by Nacimbio gets a 49% stake in SIA Group owned by Marathon Group while providing for the possibility of a significant increase in this share in the future. In turn, Marathon Group gets an option to acquire up to 100% of the shares of Nacimbio in case Nacimbio loses its status of the only supplier of medicines and medical products in accordance with the order of the authorized government body of the Russian Federation.
The scope of the deal includes shares/stake owned by the parties in the Sintez, FORT, Kirov Plasma plants and the Farm Aid Ltd., NYK Logistics, SIA Group companies.
"Integration of production sites into a single complex with a federal distributor will improve the efficiency of the government order execution with regard to providing the country's population with modern vaccines, as well as ensure the high competitiveness of the merged company in the commercial segment," comments CEO of the Rostec State Corporation Sergey Chemezov. "Strong competence in distribution and logistics that Marathon Group possesses has become a decisive factor in choosing it as a partner for the implementation of our large-scale project on the formation of a national supplier of pharmaceutical products."
"Managing our own pharmaceutical assets, we see how serious can be a multiplying effect that can arise when setting and solving a common goal. In this case, the goal is the formation of a national supplier of innovative medicines," says Alexander Vinokurov, President of Marathon Group. "We expect that by 2020, the increase in the cash flow of the joint assets will have multiplied the capitalization of Nacimbio, and it is a serious common goal for us to achieve this result. This project is the next step in the development of the group, and we are pleased that the competencies that we are consistently developing are in demand."
It should be reminded that the agreement to merge pharmaceutical assets of the Rostec State Corporation and Marathon Group on the basis of Nacimbio in order to create a manufacturer and supplier of pharmaceutical products of a federal scale was reached in August 2017. The project is an example of public and private partnership and aims to attract additional competencies and investments for the development of key directions of domestic pharmacology.